JPMorgan Chase & Co. Issues Positive Forecast for Xencor (NASDAQ:XNCR) Stock Price

Posted by Francis Steltz on May 11th, 2026

Xencor (NASDAQ:XNCR – Get Free Report) had its target price increased by investment analysts at JPMorgan Chase & Co. from $13.00 to $14.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 9.25% from the company’s previous close.

A number of other research analysts also recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Friday, March 27th. Wall Street Zen downgraded shares of Xencor from a “hold” rating to a “strong sell” rating in a research report on Saturday. Zacks Research downgraded shares of Xencor from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 6th. Finally, Barclays upped their price target on shares of Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, February 26th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $24.50.

Get Our Latest Stock Report on XNCR

Xencor Stock Down 0.3%

NASDAQ:XNCR traded down $0.05 on Monday, reaching $12.82. 369,328 shares of the company’s stock traded hands, compared to its average volume of 782,844. The stock has a 50-day simple moving average of $12.28 and a 200-day simple moving average of $13.60. The firm has a market cap of $950.13 million, a PE ratio of -5.59 and a beta of 0.93. Xencor has a 12 month low of $6.92 and a 12 month high of $18.69.

Xencor (NASDAQ:XNCR – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.96). The company had revenue of $4.52 million during the quarter, compared to analysts’ expectations of $27.86 million. Xencor had a negative return on equity of 28.77% and a negative net margin of 177.10%.The company’s revenue was down 86.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.66) EPS. On average, equities analysts anticipate that Xencor will post -3.57 earnings per share for the current year.

Insider Activity at Xencor

In other Xencor news, VP John R. Desjarlais sold 4,118 shares of Xencor stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $11.25, for a total value of $46,327.50. Following the completion of the sale, the vice president owned 266,333 shares of the company’s stock, valued at approximately $2,996,246.25. This trade represents a 1.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Bassil I. Dahiyat sold 14,870 shares of Xencor stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $11.25, for a total value of $167,287.50. Following the completion of the sale, the chief executive officer directly owned 552,922 shares of the company’s stock, valued at $6,220,372.50. The trade was a 2.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 44,020 shares of company stock valued at $499,817 in the last 90 days. Corporate insiders own 4.76% of the company’s stock.

Institutional Investors Weigh In On Xencor

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in XNCR. Primecap Management Co. CA grew its stake in shares of Xencor by 1.4% during the third quarter. Primecap Management Co. CA now owns 10,675,022 shares of the biopharmaceutical company’s stock valued at $125,218,000 after buying an additional 147,700 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Xencor by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 7,165,450 shares of the biopharmaceutical company’s stock valued at $109,703,000 after buying an additional 61,692 shares during the last quarter. BVF Inc. IL grew its stake in shares of Xencor by 160.3% during the fourth quarter. BVF Inc. IL now owns 7,133,720 shares of the biopharmaceutical company’s stock valued at $109,217,000 after buying an additional 4,393,579 shares during the last quarter. RTW Investments LP grew its stake in Xencor by 8.9% in the fourth quarter. RTW Investments LP now owns 6,777,461 shares of the biopharmaceutical company’s stock worth $103,763,000 after purchasing an additional 556,407 shares in the last quarter. Finally, State Street Corp grew its stake in Xencor by 22.7% in the fourth quarter. State Street Corp now owns 4,507,254 shares of the biopharmaceutical company’s stock worth $69,006,000 after purchasing an additional 833,423 shares in the last quarter.

Xencor Company Profile

(Get Free Report)

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.